Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,523.00
  • Today's Change15.50 / 1.03%
  • Shares traded312.38k
  • 1 Year change-33.14%
  • Beta0.3138
Data delayed at least 20 minutes, as of Nov 25 2022 16:35 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Hikma Pharmaceuticals PLC had little change in net income (from 431.00m to 421.00m) despite revenues that grew 9.06% from 2.34bn to 2.55bn. A contributing factor has been an increase in the cost of goods sold as a percent of sales from 48.18% to 49.04%.
Gross margin51.29%
Net profit margin13.57%
Operating margin19.76%
Return on assets7.75%
Return on equity15.49%
Return on investment9.99%
More ▼

Cash flow in USDView more

In 2021, Hikma Pharmaceuticals PLC increased its cash reserves by 31.89%, or 103.00m. The company earned 638.00m from its operations for a Cash Flow Margin of 24.99%. In addition the company used 238.00m on investing activities and also paid 287.00m in financing cash flows.
Cash flow per share1.89
Price/Cash flow per share7.69
Book value per share8.17
Tangible book value per share3.48
More ▼

Balance sheet in USDView more

Hikma Pharmaceuticals PLC has a Debt to Total Capital ratio of 41.45%, a higher figure than the previous year's 32.79%.
Current ratio2.12
Quick ratio1.37
Total debt/total equity0.7128
Total debt/total capital0.4145
More ▼

Growth rates in USD

Year on year, growth in dividends per share increased 8.70% while earnings per share excluding extraordinary items fell by -0.22%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
Div yield(5 year avg)0.02%
Div growth rate (5 year)11.07%
Payout ratio (TTM)36.13%
EPS growth(5 years)22.23
EPS (TTM) vs
TTM 1 year ago
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.